Year Guidance as Prolia Slides 45% — BigGo Finance
Amgen Inc (AMGN) reported Q3 earnings of $6.45 per share, beating estimates, and raised full-year guidance. Revenue grew 8% to $10.4 billion, driven by Repatha, Imdelltra, and Uprisna. However, Prolia sales fell 45% due to competition. Analysts remain cautious about pipeline progress and valuation.
How this was made
The 30-second read
Why it matters
The earnings beat combined with raised guidance provides a fresh catalyst for the stock, though product erosion and pipeline risk remain concerns.
Market read
The guidance lift is a primary earnings event for a large‑cap biotech, likely influencing short‑term price action and sector sentiment.
What to watch
Upcoming Phase 3 readouts for MariTide and potential competition in osteoporosis could temper the rally.
Background
Amgen reported Q3 2026 results, beating EPS and revenue expectations, while highlighting a 45% drop in Prolia sales.
Ticker impact
Amgen raised its full-year adjusted EPS guidance to $22.90‑$23.70 and revenue to $38.9‑$39.7 B, a fresh disclosure from its Q3 earnings release.
potential upward pressure as investors price in higher earnings expectations
Guidance lift is material, above consensus and follows a beat; market typically reacts positively to such upgrades.
Market effects
Biotech sector may see modest uplift as Amgen's guidance signals demand for its pipeline drugs.
U.S. large‑cap biotech index could gain modestly.
Limited to investors tracking major pharma earnings; no broad macro effect.
Counterpoint
Some analysts argue the guidance is already priced in and the erosion of Prolia and Xgeva could offset upside.
Key entities
- companyAmgen Inc.
Biopharma company delivering Q3 earnings and new full‑year guidance.
